SCHEMBL3382443

SCHEMBL3382443

CCCCCOS([O])(=O)=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 15/20 0.62
CA2 P00918 15/20 0.62
CA9 Q16790 13/20 0.62
CA12 O43570 4/20 0.60
CA7 P43166 4/20 0.60
CA14 Q9ULX7 4/20 0.60
CA3 P07451 3/20 0.60
CA4 P22748 3/20 0.60
CA6 P23280 3/20 0.60
CA5A P35218 3/20 0.60
CA5B Q9Y2D0 3/20 0.60
RECQL P46063 2/20 0.58
TSHR P16473 2/20 0.58
GLA P06280 1/20 0.58
HPGD P15428 1/20 0.58
MAPK1 P28482 1/20 0.58
EPHX2 P34913 1/20 0.58
BLM P54132 1/20 0.58
KDM4E B2RXH2 1/20 0.48
USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3381868 0.97 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL18207385 0.97 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL3383864 0.97 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL2672727 0.97 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL456205 0.97 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL7026427 0.97 CA1 (0.64) CA1CA2CA9CA12CA7
SCHEMBL2672190 0.92
SCHEMBL106505 0.81 CA1 (0.65) CA1CA2CA9CA12CA7
SCHEMBL456606 0.80
SCHEMBL474049 0.79 CA1 (0.67) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024037851-A1 USE OF ADDITIVES FOR IMPROVING THE PROCESSING OF POLYETHYLENES BASF SE (DE) 2024-02-22 WO disclosed
US-10270038-B2 Fullerene derivative, organic solar cell using same, and preparation method therefor LG CHEM, LTD. (KR) 2019-04-23 US disclosed
EP-3103801-B1 FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND PREPARATION METHOD THEREFOR LG CHEMICAL LTD (KR) 2018-07-04 EP disclosed
EP-3103801-A1 FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND PREPARATION METHOD THEREFOR LG Chem, Ltd. (KR) 2016-12-14 EP disclosed
US-20160329499-A1 FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND PREPARATION METHOD THEREFOR LG CHEM, LTD. (KR) 2016-11-10 US disclosed
US-20130210973-A1 PROCESS FOR IMPROVING THE FLOW PROPERTIES OF POLYMER MELTS BASF SE (DE) 2013-08-15 US disclosed
US-8227541-B2 Additive mixtures BASF SE (DE) 2012-07-24 US disclosed
EP-1668072-B1 ADDITIVE MIXTURES BASF SE (DE) 2010-11-24 EP disclosed
US-20090318593-A1 Process for Improving the Flow Properties of Polymer Melts UNIVERSITAT BAYREUTH (DE) 2009-12-24 US disclosed
US-20090111719-A1 Additive mixtures STOLL KLAUS 2009-04-30 US disclosed
EP-1928936-A1 PROCESS FOR IMPROVING THE FLOW PROPERTIES OF POLYMER MELTS Ciba Holding Inc. (CH) 2008-06-11 EP disclosed
WO-2007053869-A2 NOVEL 2,2-DITHIOSUBSTITUTED FURANOSE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF SAISCHEK UND PARTNER MEG (AT) 2007-05-18 WO disclosed
WO-2007039471-A1 PROCESS FOR IMPROVING THE FLOW PROPERTIES OF POLYMER MELTS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2007-04-12 WO disclosed
US-20070032581-A1 Additive mixtures CIBA CORPORATION 2007-02-08 US disclosed
EP-1668072-A2 ADDITIVE MIXTURES Ciba SC Holding AG (CH) 2006-06-14 EP disclosed
WO-2005030855-A2 ADDITIVE MIXTURES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2005-04-07 WO disclosed
US-5231101-A Antihistamines SS PHARMACEUTICAL CO., LTD. (JP) 1993-07-27 US disclosed
EP-0495484-A1 Novel benzo [5,6] cyclohepta [1,2-b] pyridine derivatives and antiallergic agents comprising same SS PHARMACEUTICAL CO., LTD. (JP) 1992-07-22 EP disclosed
EP-0028099-A1 Photographic couplers, emulsions, materials and processes EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1981-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160329499-A1 FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND PREPARATION METHOD THEREFOR WEE2, WEE1, STOML2 CA1 1880/4885CA2 2634/4885CA9 1746/4885
US-10270038-B2 Fullerene derivative, organic solar cell using same, and preparation method therefor WEE2, WEE1, STOML2 CA1 1880/4885CA2 2634/4885CA9 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.